ESR1 and prostate carcinoma: To determine whether these dynamic and static TF-TF interactions were unique to the liver, we analyzed six additional cell line ESR1 ChIP-Seq datasets: endometrial cancer (ECC1) [24], endometrial adenocarcinoma (Ishikawa) [31], prostate cancer (VCaP) [32], osteosarcoma (U2OS) [33], ovarian cancer (SKOV3) [34], and breast cancer (MCF-7) [35].